Okay, thanks.
Coming back to the discussion of private-pay and orphan drugs and rare drugs versus a public system, you said in your report that a national pharmacare program would eliminate the huge variation in the time to access orphan drugs, implying to me that this would be a better, more robust model, and that there would be less of a dichotomy in how they come forward. However, you thought it needed to be tied into conditional licensing and a national reimbursement process. Could you just talk about that a little bit, and would you offer maybe a slightly different view than Dr. Wong-Rieger did on a private versus public system, and the market?